ATAI Life Sciences NV (ATAI)
1.17
-0.02
(-1.68%)
USD |
NASDAQ |
Sep 27, 16:00
1.175
0.00 (0.00%)
After-Hours: 20:00
ATAI Life Sciences Cash from Investing (Quarterly): 16.30M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 16.30M |
| March 31, 2024 | 11.47M |
| December 31, 2023 | -0.823M |
| September 30, 2023 | -46.48M |
| June 30, 2023 | -22.00M |
| March 31, 2023 | 16.02M |
| December 31, 2022 | 80.05M |
| September 30, 2022 | 66.05M |
| June 30, 2022 | -18.21M |
| Date | Value |
|---|---|
| March 31, 2022 | -214.74M |
| December 31, 2021 | -48.63M |
| September 30, 2021 | -0.614M |
| June 30, 2021 | -28.31M |
| March 31, 2021 | -3.721M |
| December 31, 2020 | -3.866M |
| September 30, 2020 | -5.376M |
| June 30, 2020 | -0.306M |
| March 31, 2020 | -18.72M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-214.74M
Minimum
Mar 2022
80.05M
Maximum
Dec 2022
-12.33M
Average
-3.794M
Median
Cash from Investing (Quarterly) Benchmarks
| Affimed NV | 12.50M |
| InflaRx NV | 6.200M |
| BioNTech SE | -238.16M |
| Immatics NV | 77.47M |
| CureVac NV | -8.014M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -16.23M |
| Cash from Financing (Quarterly) | 0.326M |
| Free Cash Flow | -79.22M |
| Free Cash Flow Per Share (Quarterly) | -0.1012 |
| Free Cash Flow to Equity (Quarterly) | -15.13M |
| Free Cash Flow to Firm (Quarterly) | -15.64M |
| Free Cash Flow Yield | -40.74% |